Oculis Appoints Snehal Shah, PharmD, as President of Research & Development

Oculis announced the appointment of Snehal Shah, PharmD, executive leader with over two decades of research & development (R&D) and regulatory experience, to the role of President of R&D.

In this new role, Dr. Shah will be responsible for leading research and development strategies, and working toward achieving market authorizations by directing global regulatory activities required for future new drug application (NDA) submissions to the FDA, and the equivalent for regulators in other territories.

Dr. Shah joins Oculis from Iveric Bio, where he served as Chief Regulatory & Product Strategy Officer and led the approval of Izervay for geographic atrophy in the US. He brings more than 20 years of global experience in regulatory science, research & development, pharmacovigilance, and product strategy gained at leading large, medium and biotech pharmaceutical companies, including Hoffmann La-Roche / Genentech, Noven Pharmaceuticals (Member of the Hisamitsu Group), Kyowa Kirin and Iveric Bio. 

“I am thrilled to join the exceptionally talented team at Oculis to lead R&D activities during a period of significant momentum and expansion which comes as we advance our leading candidate OCS-01 through phase 3 trials towards our first anticipated NDA submission and expect the OCS-02 RELIEF phase 2b trial results this quarter," Dr. Shah said. "Oculis’ highly diversified pipeline provides an opportunity to be part of an endeavour that aims to shift the treatment paradigm for ocular disorders, supporting patients throughout their disease continuum, which can lead to vision loss and ultimately blindness.”